Search Within

Martin Stuart Tallman

  1. "2016"
Formats
  1. Meeting Abstract (33)
  2. Journal Article (31)
Groups
  1. Adult Leukemia (64)
  2. Center for Hematologic Malignancies (64)
  3. Department of Medicine (64)
  4. Hematologic Malignancies, Division of (64)
  5. GSK Faculty (20)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (18)

More Groups

People
  1. Ross Levine (16)
  2. Sean Devlin (12)
  3. Dan Douer (10)
  4. Jae Park (9)
  5. Bartlomiej Getta (6)
  6. Eytan Stein (6)

More People

Years
  1. 2016 (64)
Publications
  1. Blood (28)
  2. Journal of Clinical Oncology (6)
  3. Haematologica (4)
  4. American Journal of Hematology (3)
  5. Bone Marrow Transplantation (2)
  6. Clinical Lymphoma, Myeloma and Leukemia (2)

More Publications

Publishers
  1. American Society of Hematology (29)
  2. American Society of Clinical Oncology (6)
  3. Nature Publishing Group (6)
  4. Ferrata Storti Foundation (4)
  5. Elsevier Inc. (3)
  6. John Wiley & Sons, Inc. (3)

More Publishers

Results (64)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Crenolanib, a type I FLT3 TKI, can be safely combined with cytarabine and anthracycline induction chemotherapy and results in high response rates in patients with newly diagnosed FLT3 mutant acute myeloid leukemia (AML)
    Meeting Abstract

    Wang, E. S.; Stone, R. M.; Tallman, M. S.; Walter, R. B.; Eckardt, J. R.; Collins, R.
    Blood (2016)

    Fulltext@MSK | Save
  • Prevalence of clonal hematopoiesis in patients with advanced cancer
    Meeting Abstract

    Zehir, A.; Coombs, C. C.; Devlin, S.; Kishtagari, A.; Hyman, D. M.; Solit, D. B.; Robson, M. E.; Baselga, J.; Arcila, M. E.; Tallman, M. S.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase III randomized, open-label study comparing the efficacy and safety of AG-221 vs conventional care regimens (CCR) in older patients with advanced acute myeloid leukemia (AML) with isocitrate dehydrogenase (IDH)-2 mutations in relapse or refractory to multiple prior treatments: The IDHENTIFY trial
    Meeting Abstract

    Tallman, M. S.; Knight, R. D.; Glasmacher, A. G.; Dohner, H.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase 1, open-label, dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT-301 in patients with relapsed or refractory CD25-positive acute myeloid leukemia
    Meeting Abstract

    Tallman, M. S.; Feingold, J. M.; Spira, A. I.; Rizzieri, D.; Atallah, E. L.; Stock, W.; Jain, N.; Walter, R. B.; Chung, K. Y.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR)
    Meeting Abstract

    Maslak, P. G.; Dao, T.; Bernal, Y.; Chanel, S. M.; Zhang, R.; Frattini, M. G.; Rosenblat, T. L.; Jurcic, J. G.; Rampal, R.; Park, J. H.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • RNA binding protein SYNCRIP regulates the leukemia stem cell program
    Meeting Abstract

    Vu, L. P.; Prieto, C.; Amin, E.; Minuesa, G.; Chhangawala, S.; Vidal, M. J.; Krivtsov, A. V.; Chou, T.; Barlowe, T.; Taggart, J.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Enasidenib (AG-221), a potent oral inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzyme, induces hematologic responses in patients with myelodysplastic syndromes (MDS)
    Meeting Abstract

    Stein, E. M.; Fathi, A. T.; DiNardo, C. D.; Pollyea, D. A.; Swords, R. T.; Roboz, G. J.; Collins, R.; Sekeres, M. A.; Stone, R. M.; Attar, E. C.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • ATRA, arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO) is safe and highly effective in patients with previously untreated high-risk acute promyelocytic leukemia (APL): Final results of the SWOG/Alliance/ECOG S0535 trial
    Meeting Abstract

    Lancet, J. E.; Moseley, A.; Komrokji, R. S.; Coutre, S. E.; DeAngelo, D. J.; Tallman, M. S.; Litzow, M.; Othus, M.; Appelbaum, F. R.
    Blood (2016)

    Fulltext@MSK | Save
  • Combined treatment with lenalidomide (LEN) and epoetin alfa (EA) is superior to lenalidomide alone in patients with erythropoietin (Epo)-refractory, lower risk (LR) non-deletion 5q [Del(5q)] myelodysplastic syndrome (MDS): Results of the E2905 Intergroup Study - an ECOG-ACRIN Cancer Research Group study, grant CA180820, and the National Cancer Institute of the National Institutes of Health
    Meeting Abstract

    List, A. F.; Sun, Z.; Verma, A.; Bennett, J. M.; McGraw, K. L.; Nardelli, L. A.; Maciejewski, J. P.; Altman, J. K.; Cheema, P.; Claxton, D. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Pembrolizumab, a PD-1 inhibitor, in patients with myelodysplastic syndrome (MDS) after failure of hypomethylating agent treatment
    Meeting Abstract

    Garcia-Manero, G.; Tallman, M. S.; Martinelli, G.; Ribrag, V.; Yang, H.; Balakumaran, A.; Chlosta, S.; Zhang, Y.; Smith, B. D.
    Blood (2016)

    Fulltext@MSK | Save